BACKGROUND: Tumour cell lines represent valuable preclinical models to decipher underlying biology and identify potential therapy targets and pharmacologically useful compounds. Approximately 50 human bladder cancer cell lines have been established to date, mainly from invasive and metastatic tumours. Two of these, namely T24 and 253J, were experimentally further developed into progression series. These models have provided important insights into later tumour progression events and metastatic dissemination. Only a few cell lines are available as models of non-invasive papillary bladder cancer and no progression series have yet been established. MATERIAL AND METHODS: During the course of establishing a doxorubicin-resistant variant cell line of the human papillary bladder carcinoma cell line BFTC-905, a unique cell colony was identified, apparently involving cells with divergent growth patterns. Subsequent subculturing yielded three daughter cell lines, BFTC-905-compact, BFTC-905-diffuse und BFTC-905-diffuse M. Their fundamental characterization included basic cell morphology, cell membrane expression of E-Cadherin, karyotype analysis, invasion and colony forming capacity in soft agar. The clonal origin of the newly established daughter cell lines was assessed by means of molecular genetic methods. RESULTS: We could identify important differences in multiple transformation related traits among the cell lines of the BFTC-905 progression series. Both diffuse cell lines (BFTC-905-diffuse und BFTC-905-diffuse M) differed from the BFTC-905-compact cell line by growing in a less organized,"diffuse" manner, which involved colonies of cells exhibiting apparently normal cell-to-cell adhesion as well as individual cells outside of them. This diminution of the cell-to-cell adhesion was accompanied by a corresponding decrease of membranous E-Cadherin. The BFTC-905-diffuse M cell line displayed a dramatic increase in the overall chromosome number, resulting in a hypertetraploid karyotype. At the same time, this cell line, as the only one in the progression series, acquired the ability to grow independent of anchorage in soft agar. All three cell lines remained noninvasive. Allelic distribution of highly polymorphic DNA-markers in the cell lines of the BFTC-905 progression series provided unequivocal evidence of their common origin. CONCLUSION: The newly established BFTC-905 progression series manifests two aspects of the early progression of non-invasive bladder carcinoma, not exhibited by any other progression series published so far, namely dynamic changes in the expression of E-Cadherin and a complex karyotypic evolution. It may thus contribute important insights into further understanding of the pathobiology of bladder cancer.
BACKGROUND:Tumour cell lines represent valuable preclinical models to decipher underlying biology and identify potential therapy targets and pharmacologically useful compounds. Approximately 50 humanbladder cancer cell lines have been established to date, mainly from invasive and metastatic tumours. Two of these, namely T24 and 253J, were experimentally further developed into progression series. These models have provided important insights into later tumour progression events and metastatic dissemination. Only a few cell lines are available as models of non-invasive papillary bladder cancer and no progression series have yet been established. MATERIAL AND METHODS: During the course of establishing a doxorubicin-resistant variant cell line of the humanpapillary bladder carcinoma cell line BFTC-905, a unique cell colony was identified, apparently involving cells with divergent growth patterns. Subsequent subculturing yielded three daughter cell lines, BFTC-905-compact, BFTC-905-diffuse und BFTC-905-diffuse M. Their fundamental characterization included basic cell morphology, cell membrane expression of E-Cadherin, karyotype analysis, invasion and colony forming capacity in soft agar. The clonal origin of the newly established daughter cell lines was assessed by means of molecular genetic methods. RESULTS: We could identify important differences in multiple transformation related traits among the cell lines of the BFTC-905 progression series. Both diffuse cell lines (BFTC-905-diffuse und BFTC-905-diffuse M) differed from the BFTC-905-compact cell line by growing in a less organized,"diffuse" manner, which involved colonies of cells exhibiting apparently normal cell-to-cell adhesion as well as individual cells outside of them. This diminution of the cell-to-cell adhesion was accompanied by a corresponding decrease of membranous E-Cadherin. The BFTC-905-diffuse M cell line displayed a dramatic increase in the overall chromosome number, resulting in a hypertetraploid karyotype. At the same time, this cell line, as the only one in the progression series, acquired the ability to grow independent of anchorage in soft agar. All three cell lines remained noninvasive. Allelic distribution of highly polymorphic DNA-markers in the cell lines of the BFTC-905 progression series provided unequivocal evidence of their common origin. CONCLUSION: The newly established BFTC-905 progression series manifests two aspects of the early progression of non-invasive bladder carcinoma, not exhibited by any other progression series published so far, namely dynamic changes in the expression of E-Cadherin and a complex karyotypic evolution. It may thus contribute important insights into further understanding of the pathobiology of bladder cancer.
Authors: Tobias Zellweger; Gabriel Benz; Gieri Cathomas; Michael J Mihatsch; Tullio Sulser; Thomas C Gasser; Lukas Bubendorf Journal: Int J Cancer Date: 2006-10-01 Impact factor: 7.396
Authors: John J Gildea; M Jabed Seraj; Gary Oxford; Michael A Harding; Garret M Hampton; Christopher A Moskaluk; Henry F Frierson; Mark R Conaway; Dan Theodorescu Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: C P Dinney; R Fishbeck; R K Singh; B Eve; S Pathak; N Brown; B Xie; D Fan; C D Bucana; I J Fidler Journal: J Urol Date: 1995-10 Impact factor: 7.450
Authors: Hans-Helge Seifert; Andrea Meyer; Marcus V Cronauer; Jiri Hatina; Mirko Müller; Harald Rieder; Michele J Hoffmann; Rolf Ackermann; Wolfgang A Schulz Journal: World J Urol Date: 2007-04-18 Impact factor: 3.661
Authors: Anja Rogler; Emil Kendziorra; Johannes Giedl; Christine Stoehr; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr Journal: J Cancer Res Clin Oncol Date: 2015-03-04 Impact factor: 4.553
Authors: Camila B Piantino; Juliana M Sousa-Canavez; Victor Srougi; Fernanda Salvadori; Raphael Kato; Pedro Paulo R Ayres; Miguel Srougi; Luiz Heraldo Camara-Lopes; Gilka Jorge Figaro Gattás; Cintia Fridman; Fernanda de Toledo; Isaque Santana; Kátia Ramos Moreira Leite Journal: In Vitro Cell Dev Biol Anim Date: 2010-02 Impact factor: 2.416
Authors: Anja Rogler; Sabine Hoja; Eileen Socher; Elke Nolte; Sven Wach; Wolf Wieland; Ferdinand Hofstädter; Peter J Goebell; Bernd Wullich; Arndt Hartmann; Robert Stoehr Journal: Int J Clin Exp Pathol Date: 2013-09-15
Authors: Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real Journal: BMC Genomics Date: 2015-05-22 Impact factor: 3.969
Authors: Anja Rogler; Sabine Hoja; Johannes Giedl; Arif B Ekici; Sven Wach; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr Journal: BMC Cancer Date: 2014-03-20 Impact factor: 4.430